Your browser doesn't support javascript.
loading
Second annual report from the ISSPP PIPAC database.
Mortensen, Michael Bau; Casella, Francesco; Düzgün, Özgül; Glehen, Olivier; Hewett, Peter; Hübner, Martin; Jørgensen, Magnus Skov; Königsrainer, Alfred; Marin, Miguel; Pocard, Marc; Rezniczek, Günther; So, Jimmy; Fristrup, Claus Wilki.
Afiliación
  • Mortensen MB; Upper GI and HPB Section, Department of Surgery, Odense Universitetshospital, Odense, Denmark.
  • Casella F; General and Upper GI Surgery, University of Verona, Verona, Veneto, Italy.
  • Düzgün Ö; Department of Surgical Oncology, Istanbul Ümraniye Training and Research Hospital, Istanbul, Türkiye.
  • Glehen O; Service de Chirurgie Digestive et Oncologique, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.
  • Hewett P; Department of Surgery, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.
  • Hübner M; Lausanne University Hospital CHUV, University of Lausanne, Lausanne, Switzerland.
  • Jørgensen MS; Department of Surgery, Odense University Hospital, Odense, Denmark.
  • Königsrainer A; Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
  • Marin M; Department of Surgery, Reina Sofia University General Hospital, Murcia, Spain.
  • Pocard M; Surgical Unit, Paris 7 University, Paris, France.
  • Rezniczek G; Obstetrics & Gynecology, Ruhr-Universität Bochum, Herne, Germany.
  • So J; Surgery, National University Hospital, Singapore, Singapore.
  • Fristrup CW; Department of Surgery, Odense University Hospital, Odense, Denmark.
Pleura Peritoneum ; 8(4): 141-146, 2023 Dec.
Article en En | MEDLINE | ID: mdl-38144218
ABSTRACT

Objectives:

To monitor the results of PIPAC directed therapy based on data from the International Society for the Study of the Pleura and Peritoneum (ISSPP) PIPAC database.

Methods:

Analysis of data from patients entered between June 15th, 2020, and February 28th, 2023.

Results:

Twelve centers reported 2,456 PIPAC procedures in 809 patients (median 2, range 1-18) with peritoneal metastasis (PM) from different primary tumors. Approximately 90 % had systemic chemotherapy prior to PIPAC. Twenty-eight percent were treated in prospective protocols. Overall non-access rate was 3.5 %. Concomitant surgical procedures were performed during PIPAC in 1.6 % of the patients. Median length of stay was 2 days. A total of 95 surgical complications were recorded, but only 22 % of these were graded ≥3b. Seventeen-hundred-and-three adverse events were noted, and 8 % were classified ≥3. The rate of complete or major histological response (peritoneal regression grade score, PRGS≤2) increased between the first and the third PIPAC in the group of patients who were evaluated by PRGS, and a PRGS ≤2 or a reduction of the mean PRGS of at least 1 between first and third PIPAC were observed in 80 %. Disease progression (50 %) or technical issues (19 %) were the most important reasons for stopping PIPAC treatment. Median overall survival from first PIPAC directed treatment varied from 10.7 months (CI 8.7-12.5) in gastric cancer to 27.1 months (16.4-50.5) in mesothelioma.

Conclusions:

The ISSPP PIPAC database provides substantial real-world data supporting the use of PIPAC directed therapy in patients with PM from different primary tumors.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pleura Peritoneum Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Pleura Peritoneum Año: 2023 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Alemania